RB1 and head and neck squamous cell carcinoma: Alisertib is being widely evaluated in various tumor indications, with seven ongoing early-phase clinical trials including a phase-I/II trial in Rb-deficient HPV-positive HNSCC in combination with a PD-1-inhibitor (NCT04555837).